Tredje AP fonden Has $553,000 Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Tredje AP fonden decreased its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 50.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,684 shares of the medical research company's stock after selling 1,683 shares during the period. Tredje AP fonden's holdings in Bio-Rad Laboratories were worth $553,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Wealthfront Advisers LLC bought a new stake in shares of Bio-Rad Laboratories during the 4th quarter worth $342,686,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Bio-Rad Laboratories by 1.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 441,098 shares of the medical research company's stock worth $147,583,000 after acquiring an additional 4,260 shares in the last quarter. Westfield Capital Management Co. LP raised its holdings in shares of Bio-Rad Laboratories by 3.9% during the third quarter. Westfield Capital Management Co. LP now owns 252,769 shares of the medical research company's stock valued at $84,571,000 after acquiring an additional 9,584 shares during the period. Point72 Asset Management L.P. purchased a new stake in shares of Bio-Rad Laboratories in the 3rd quarter valued at approximately $83,681,000. Finally, Mawer Investment Management Ltd. boosted its stake in Bio-Rad Laboratories by 63.0% in the 3rd quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company's stock worth $72,900,000 after purchasing an additional 84,237 shares during the period. Institutional investors and hedge funds own 65.24% of the company's stock.

Remove Ads

Analyst Ratings Changes

Several brokerages have issued reports on BIO. Wells Fargo & Company cut their target price on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 12th. StockNews.com downgraded Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Monday, February 17th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $481.00 target price on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Bio-Rad Laboratories presently has a consensus rating of "Moderate Buy" and an average price target of $395.20.

Bio-Rad Laboratories Stock Down 2.5 %

BIO traded down $6.54 during trading on Wednesday, reaching $253.49. 356,370 shares of the stock traded hands, compared to its average volume of 267,165. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.48 and a quick ratio of 4.85. Bio-Rad Laboratories, Inc. has a fifty-two week low of $244.00 and a fifty-two week high of $387.99. The stock's 50-day simple moving average is $308.56 and its two-hundred day simple moving average is $326.91. The stock has a market cap of $7.10 billion, a price-to-earnings ratio of -3.90 and a beta of 0.98.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. As a group, equities research analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.